WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
…, O Oxlade, D Palmero, P Pavlinac, MI Quelapio… - 2011 - Eur Respiratory Soc
The production of guidelines for the management of drug-resistant tuberculosis (TB) fits the
mandate of the World Health Organization (WHO) to support countries in the reinforcement of …
mandate of the World Health Organization (WHO) to support countries in the reinforcement of …
[HTML][HTML] Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients
…, G Pasvol, J Peña, C Pérez-Guzmán, MID Quelapio… - 2012 - journals.plos.org
Background Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic,
expensive, and has generally poor outcomes. We undertook an individual patient data meta-…
expensive, and has generally poor outcomes. We undertook an individual patient data meta-…
Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects
…, MI Quelapio, V Riekstina, P Viiklepp, M Zignol… - Tuberculosis, 2012 - Elsevier
The Objective of this analysis was to identify predictors of death, failure, and default among
MDR-TB patients treated with second-line drugs in DOTS-plus projects in Estonia, Latvia, …
MDR-TB patients treated with second-line drugs in DOTS-plus projects in Estonia, Latvia, …
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion
…, RD Mugerwa, MR Alcaneses, MI Quelapio… - American journal of …, 2009 - atsjournals.org
Rationale: Cavitary disease and delayed culture conversion have been associated with
relapse. Combining patient characteristics and measures of bacteriologic response might allow …
relapse. Combining patient characteristics and measures of bacteriologic response might allow …
[HTML][HTML] Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines
TE Tupasi, R Gupta, MID Quelapio, RB Orillaza… - PLoS …, 2006 - journals.plos.org
Background Multidrug-resistant tuberculosis (MDR-TB) is an important global health problem,
and a control strategy known as DOTS-Plus has existed since 1999. However, evidence …
and a control strategy known as DOTS-Plus has existed since 1999. However, evidence …
Surgery as an adjunctive treatment for multidrug-resistant tuberculosis: an individual patient data metaanalysis
…, A Ponce-de-Leon, MID Quelapio… - Clinical Infectious …, 2016 - academic.oup.com
Background. Medical treatment for multidrug-resistant (MDR)-tuberculosis is complex, toxic,
and associated with poor outcomes. Surgical lung resection may be used as an adjunct to …
and associated with poor outcomes. Surgical lung resection may be used as an adjunct to …
Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis
…, V Leimane, CD Mitnick, MI Quelapio… - … of tuberculosis and …, 2012 - ingentaconnect.com
OBJECTIVE: To identify predictors of initial sputum culture conversion, estimate the usefulness
of persistent positive cultures at different time points in predicting treatment failure, and …
of persistent positive cultures at different time points in predicting treatment failure, and …
[HTML][HTML] Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes
LJ Podewils, MTS Gler, MI Quelapio, MP Chen - PLoS One, 2013 - journals.plos.org
… Interruptions during the 6–12 and 12–18 month periods of MDR TB treatment may be
particularly critical, when the patient is expressing clinical improvement but the M. tuberculosis has …
particularly critical, when the patient is expressing clinical improvement but the M. tuberculosis has …
Estimating the contribution of subclinical tuberculosis disease to transmission: An individual patient data analysis from prevalence surveys
Background: Individuals with bacteriologically confirmed pulmonary tuberculosis (TB) disease
who do not report symptoms (subclinical TB) represent around half of all prevalent cases …
who do not report symptoms (subclinical TB) represent around half of all prevalent cases …
QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment
…, J Furin, CY Chiang, M Quelapio… - … of Tuberculosis and …, 2018 - ingentaconnect.com
Multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (XDR-TB) are global
concerns, with stagnant treatment success rates of roughly 54% and 30%, respectively. …
concerns, with stagnant treatment success rates of roughly 54% and 30%, respectively. …